What the clinical evidence shows

Eighty-one per cent of evaluable patients achieved good or excellent results — that is the headline figure from the most detailed hip-specific study of ChondroFiller published to date. Mazek et al. (2021) followed 26 adults with acetabular cartilage lesions greater than 2 cm², all treated arthroscopically alongside femoroacetabular impingement correction, for between 12 and 60 months. Of the 21 patients who completed follow-up, 17 met the threshold for a good or excellent outcome.

Mid-term joint preservation data reinforce that picture. The implant survival rate — defined as no revision procedure and no conversion to total hip replacement — was 92.3% across the cohort. Two patients (approximately 7.7%) did ultimately require total hip arthroplasty, a figure that sits within the range reported for other cartilage repair techniques at comparable follow-up intervals.

Aggregated outcome data drawn from hip cohorts add further quantitative texture. Across published series, 70–85% of patients report good-to-very-good symptom relief, and mean improvement on the modified Harris Hip Score is approximately 33 points — a clinically meaningful functional gain. A second peer-reviewed study, Pérez-Carro et al. (2021), independently confirmed ChondroFiller as a viable single-step arthroscopic option for full-thickness acetabular defects, describing promising results while calling for larger, longer-term work.

These figures derive from small prospective cohorts rather than large randomised controlled trials. They represent the best available hip-specific clinical data for this procedure, and they are consistent enough across independent groups to provide a credible evidence base for informed decision-making.

Which patients get the best results

Patient selection is the single strongest predictor of outcome with ChondroFiller — more so than defect size alone. The procedure is best suited to patients with early-stage hip arthritis or no arthritis at all: in clinical terms, Tönnis Grade 0 (normal joint) or Grade 1 (minor changes without joint-space narrowing). Both peer-reviewed hip cohorts — Mazek et al. and Pérez-Carro et al. — consistently identify this group as achieving the best results.

Patients classified as Tönnis Grade 2 or 3 — moderate to severe osteoarthritis — produced poor outcomes in the hip-specific data. This is a clinical contraindication, not a borderline caution; the published evidence does not support offering ChondroFiller to patients with established OA at these grades.

The target indication is a focal, isolated acetabular or femoral head defect with healthy surrounding cartilage. Diffuse cartilage loss or widespread joint degeneration falls outside the procedure's evidence base. The presence of femoroacetabular impingement (FAI) does not exclude a patient — both hip studies enrolled FAI patients — but the underlying impingement should be corrected concurrently.

Age and body-mass index are also weighed during assessment. Younger patients with lower BMI tend to have more favourable mechanical conditions for repair-tissue maturation; neither factor operates as a fixed cut-off in the published studies, but both influence the overall clinical picture that a specialist considers.

Even in the most suitable candidates, a good outcome cannot be guaranteed. A specialist hip assessment is the appropriate next step to establish whether ChondroFiller is a realistic option for a specific patient.

How ChondroFiller works in the hip joint

ChondroFiller is a CE-marked Class III acellular collagen scaffold — not a drug, not a steroid, and not a lubricant. Classified as a medical device, it contains no living cells. Once placed into a focal cartilage defect, the liquid collagen gels in situ, forming a three-dimensional matrix into which the patient's own progenitor cells — drawn from the local synovium and subchondral bone — migrate and begin to differentiate. This process, known as acellular matrix-induced chondrogenesis, supports the body's own repair processes via the scaffold rather than delivering cells or growth factors directly. The collagen matrix is not a permanent filler; it is progressively remodelled as host cells generate repair tissue, typically over six to twelve months.

At Lincolnshire Hip, ChondroFiller is delivered as an ultrasound-guided outpatient injection placed directly into the focal defect. It is important to note that the outcome studies described above — including the 81% good-to-excellent figure and the joint-preservation data — were conducted using arthroscopic delivery. Direct clinical data for the ultrasound-guided injection route in the hip are currently limited, and that difference in technique is a relevant factor when interpreting published figures. Ongoing clinical experience will help clarify how closely outcomes align across delivery methods.

Patients who have heard of Arthrosamid sometimes ask how the two compare. Arthrosamid is a polyacrylamide hydrogel that functions as a mechanical cushion within the joint without initiating any regenerative cellular process — a fundamentally different role from ChondroFiller's scaffold-based mechanism.

What MRI shows after hip cartilage treatment

MRI at 6 to 18 months provides the most objective measure of repair progress. Aggregated hip outcome data indicate that over 90% of treated cases demonstrate significant defect filling and scaffold integration within this window.

Published European cohort studies use the MOCART score (Magnetic Resonance Observation of Cartilage Repair Tissue, scaled 0–100) to quantify repair quality. ChondroFiller-treated joints reach MOCART scores of 81.6–84.3, indicating more than 80% defect filling and good integration with surrounding native cartilage. Maturation is progressive rather than immediate: scores begin at approximately 65.3 at four weeks and rise to 81.6 by one year, reflecting the gradual cellular remodelling the scaffold supports.

Much of this MOCART evidence originates in knee cohorts; hip-specific imaging data are smaller in volume and still growing. For post-operative hip cartilage assessment, the current recognised standard is the MERCH score — a consensus-developed 7-domain framework covering defect fill, integration, surface contour, structure, bony overgrowth, subchondral changes, and delamination. MERCH and MOCART assess overlapping features, but dedicated MERCH data for ChondroFiller in the hip are still accumulating; the MOCART figures serve as a useful directional benchmark in the interim.

The MERCH consensus recommends waiting at least 12 months before a meaningful post-operative assessment. Cartilage maturation continues beyond that point, and an early scan should not be read as a final verdict on repair quality.

Recovery timeline and weight-bearing after hip cartilage treatment

Protecting the collagen scaffold in the weeks immediately after treatment is as important as the procedure itself. A 2024 biomechanical study confirmed that ChondroFiller is load-sensitive during initial gelation — before stable cell recruitment has occurred, mechanical stress can disrupt the forming matrix. The phased weight-bearing schedule directly reflects that finding.

Staged weight-bearing schedule

• Weeks 1–3 — non-weight-bearing. The scaffold is gelling and the first wave of progenitor cells is migrating in. Loading the joint during this window risks displacing the material before it can consolidate.
• Weeks 3–6 — partial weight-bearing. Repair tissue is beginning to mature. Graduated loading is introduced carefully, guided by comfort and clinical progress.
• Week 6 onwards — transition to full weight-bearing. As the maturing tissue gains structural integrity, normal load-bearing resumes incrementally.

Subjective improvement — reduced pain and better movement — typically begins at 6 to 12 weeks rather than immediately after the procedure. MRI maturation continues well beyond that, often over 12 months or more, so early symptom progress and final repair quality are separate milestones.

These stages are a general framework. The precise protocol agreed at your Lincolnshire Hip appointment will be tailored to your defect, your overall hip condition, and your progress at review — always follow that individualised plan rather than any generic schedule.

Getting a ChondroFiller assessment at Lincolnshire Hip

ChondroFiller is not currently available on the NHS. In the UK it is offered as a self-funded private treatment, and the first practical step for any patient considering it is a specialist hip assessment to establish whether the selection criteria — Tönnis grade, defect size, and the condition of surrounding cartilage — are met. That assessment is the same whether the conclusion is to proceed, to consider an alternative, or to monitor and review.

For patients outside London, Lincolnshire Hip offers hip cartilage consultations at its Sleaford and Grantham locations. No GP referral is required to arrange an appointment. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intactcartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z